Resumen
Clinical management of Malignant Salivary Gland Tumors is still a challenge for clinicians. Direct and indirect costs for the diagnosis and treatment of these tumors are significant. For this reason, the need to develop a fast and low-cost prognostic system to stratify patients at higher risk appears to be mandatory. The efficacy of inflammatory biomarkers such as the systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR), as prognostic values that are quickly available and low cost, has been confirmed in various fields of oncology. The aim of this study was to investigate the impact of these biomarkers taken individually and combined, to assess the overall survival (OS) in patients surgically treated for malignant salivary gland tumors. This study determined that the combination of SII + SIRI can independently predict the overall survival of patients after surgery for malignant salivary gland tumors.